Abcam (LON:ABC)‘s stock had its “neutral” rating reaffirmed by equities research analysts at JPMorgan Chase & Co. in a report issued on Monday, January 8th. They presently have a GBX 946 ($13.28) price objective on the stock. JPMorgan Chase & Co.’s target price suggests a potential downside of 23.40% from the stock’s previous close.
Several other research analysts also recently commented on ABC. Peel Hunt raised their price objective on Abcam from GBX 750 ($10.53) to GBX 1,020 ($14.32) and gave the stock a “hold” rating in a research note on Wednesday, September 20th. Berenberg Bank reiterated a “buy” rating and set a GBX 1,100 ($15.45) target price on shares of Abcam in a research report on Monday, September 11th. Numis Securities upgraded Abcam to a “buy” rating and set a GBX 1,200 ($16.85) target price for the company in a research report on Friday, January 5th. Finally, Panmure Gordon restated a “sell” rating on shares of Abcam in a report on Monday, September 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of GBX 1,009.33 ($14.17).
Abcam (LON ABC) traded up GBX 5 ($0.07) during mid-day trading on Monday, reaching GBX 1,235 ($17.34). The company’s stock had a trading volume of 421,329 shares, compared to its average volume of 281,232. Abcam has a 52 week low of GBX 9.73 ($0.14) and a 52 week high of GBX 1,245 ($17.48). The company has a market capitalization of $2,530.00 and a P/E ratio of 5,880.95.
COPYRIGHT VIOLATION NOTICE: “Abcam (LON:ABC) Rating Reiterated by JPMorgan Chase & Co.” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/01/abcam-abc-rating-reiterated-by-jpmorgan-chase-co.html.
Abcam Company Profile
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.